Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 71,275 shares of common stock. Awards were made to seven new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and have been approved by the Company's Compensation Committee. The inducement awards were granted on June 2, 2025. The options have a ten (10) year term and an exercise price of $17.72 per share, the closing price per share of the Company's common stock as reported by Nasdaq on June

Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that it will participate in and present at the 46th Annual Goldman Sachs Global Healthcare Conference in Miami, Florida on Monday, June 9, 2025, at 1:20 PM ET. Members of the Summit management team will participate in a fireside chat presentation providing a corporate overview and update on the progress of our organization, including the development of our innovative investigational bispecific antibody, ivonescimab. The presentation will be available live from our website: www.smmttx.com. An archived version of the presentation will be available on our website following the presentation. About Summ

Consistent Results Noted between Single Region HARMONi-A and Multiregional HARMONi Studies; Favorable Trends in Sub-Populations from North America and China for Both Primary Endpoints Were Observed Ivonescimab in Combination with Chemotherapy Reduces the Risk of Disease Progression or Death by 48% Compared to Chemotherapy Alone; Positive Overall Survival Trend Observed with Hazard Ratio of 0.79 HARMONi Represents the First Phase III Trial to Evaluate Ivonescimab in a Multiregional Setting Summit to Determine Timing of US BLA Filing Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced topline results from the Phase III clinical trial, HARMONi, the

Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 94,050 shares of common stock. Awards were made to nine new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and have been approved by the Company's Compensation Committee. The inducement awards were granted on May 14, 2025. The options have a ten (10) year term and an exercise price of $22.75 per share, the closing price per share of the Company's common stock as reported by Nasdaq on May 14

Ivonescimab in Combination with Chemotherapy Achieves Statistically Significant Superiority in PFS vs. Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in First-Line Treatment of Patients with Advanced Squamous NSCLC in HARMONi-6 Study Conducted by Akeso in China Enrollment Continues in Global Phase III Trial HARMONi-3 in First-Line Treatment of Patients with Metastatic NSCLC Ivonescimab Receives Approval in China as Monotherapy for First-Line Treatment for Advanced NSCLC in Tumors with Positive PD-L1 Expression: Interim Overall Survival HR = 0.777 in China for HARMONi-2 Study Conducted by Akeso Enrollment Has Begun in HARMONi-7 Global Phase III Trial in First-Line PD-L1 High, Metastatic

Interim Analysis of HARMONi-2 Shows an Overall Survival Hazard Ratio of 0.777 Favoring Ivonescimab at 39% Data Maturity, Implying a Potential Numerical 22% Reduction in the Risk of Death Compared to Pembrolizumab Ivonescimab Monotherapy Approved by NMPA in China for Front-Line PD-L1 Positive Advanced NSCLC Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today noted that Akeso, Inc. (Akeso, HKEX Code: 9926.HK) announced that ivonescimab was approved by the Chinese Health Authorities, the National Medical Products Administration (NMPA), for a second indication based on the results of the Phase III clinical trial, HARMONi-2 or AK112-303. HARMONi-2 evaluated monother

Conference Call to be Held at 4:30pm ET Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") will host an earnings call to announce its first quarter 2025 financial results and provide an operational update for the Company on Thursday, May 1, 2025, after the market closes. Summit will host a live webcast of the earnings conference call at 4:30pm ET, which will be accessible through our website, www.smmttx.com. An archived edition of the session will be available on our website. About Summit Therapeutics Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and

Ivonescimab in Combination with Chemotherapy in the HARMONi-6 Study Conducted by Akeso Is the First Known Regimen to Achieve a Clinically Meaningful Benefit over an anti-PD-(L)1 Antibody Combined with Chemotherapy in a Phase III Clinical Trial in 1L NSCLC PFS Improvement Was Observed across Tumors with PD-L1 Negative and PD-L1 Positive Expression in the HARMONi-6 Clinical Trial Conducted by Akeso Full Data Set to be Presented at an Upcoming Major Medical Conference Planned for Later This Year Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today noted that Akeso, Inc. (Akeso, HKEX Code: 9926.HK) announced that the Phase III clinical trial, HARMONi-6 or AK112-306

Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 176,915 shares of common stock. Awards were made to ten (10) new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and have been approved by the Company's Compensation Committee. The inducement awards were granted on March 31, 2025. The options have a ten (10) year term and an exercise price of $19.29 per share, the closing price per share of the Company's common stock as reported by Nasdaq on

Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 147,500 shares of common stock. Awards were made to seven new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and have been approved by the Company's Compensation Committee. The inducement awards were granted on March 17, 2025. The options have a ten (10) year term and an exercise price of $20.13 per share, the closing price per share of the Company's common stock as reported by Nasdaq on Ma

4 - Summit Therapeutics Inc. (0001599298) (Issuer)

4 - Summit Therapeutics Inc. (0001599298) (Issuer)

4 - Summit Therapeutics Inc. (0001599298) (Issuer)

4 - Summit Therapeutics Inc. (0001599298) (Issuer)

4 - Summit Therapeutics Inc. (0001599298) (Issuer)

4 - Summit Therapeutics Inc. (0001599298) (Issuer)

4 - Summit Therapeutics Inc. (0001599298) (Issuer)

4 - Summit Therapeutics Inc. (0001599298) (Issuer)

4 - Summit Therapeutics Inc. (0001599298) (Issuer)

4 - Summit Therapeutics Inc. (0001599298) (Issuer)

8-K - Summit Therapeutics Inc. (0001599298) (Filer)

8-K - Summit Therapeutics Inc. (0001599298) (Filer)

8-K - Summit Therapeutics Inc. (0001599298) (Filer)

S-8 - Summit Therapeutics Inc. (0001599298) (Filer)

10-Q - Summit Therapeutics Inc. (0001599298) (Filer)

8-K - Summit Therapeutics Inc. (0001599298) (Filer)

DEF 14A - Summit Therapeutics Inc. (0001599298) (Filer)

8-K - Summit Therapeutics Inc. (0001599298) (Filer)

8-K - Summit Therapeutics Inc. (0001599298) (Filer)

10-K - Summit Therapeutics Inc. (0001599298) (Filer)

4 - Summit Therapeutics Inc. (0001599298) (Issuer)

4 - Summit Therapeutics Inc. (0001599298) (Issuer)

4 - Summit Therapeutics Inc. (0001599298) (Issuer)

4 - Summit Therapeutics Inc. (0001599298) (Issuer)

4 - Summit Therapeutics Inc. (0001599298) (Issuer)

Leerink Partners initiated coverage of Summit Therapeutics with a rating of Underperform and set a new price target of $12.00

Citigroup upgraded Summit Therapeutics from Neutral to Buy and set a new price target of $35.00 from $23.00 previously

Cantor Fitzgerald initiated coverage of Summit Therapeutics with a rating of Overweight

Evercore ISI initiated coverage of Summit Therapeutics with a rating of Outperform and set a new price target of $30.00

Goldman initiated coverage of Summit Therapeutics with a rating of Buy and set a new price target of $42.00

Truist initiated coverage of Summit Therapeutics with a rating of Buy and set a new price target of $35.00

Wells Fargo initiated coverage of Summit Therapeutics with a rating of Overweight and set a new price target of $30.00

Jefferies initiated coverage of Summit Therapeutics with a rating of Buy and set a new price target of $31.00

JMP Securities initiated coverage of Summit Therapeutics with a rating of Mkt Outperform and set a new price target of $32.00

Citigroup downgraded Summit Therapeutics from Buy to Neutral and set a new price target of $23.00 from $19.00 previously